Difference between revisions of "Immune effector cells toxicity management"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:100%;" ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page co-editor''' !...") |
m |
||
| Line 14: | Line 14: | ||
==ASTCT== | ==ASTCT== | ||
*'''2019:''' Lee et al. [https://doi.org/10.1016/j.bbmt.2018.12.758 ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells] | *'''2019:''' Lee et al. [https://doi.org/10.1016/j.bbmt.2018.12.758 ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells] | ||
| + | |||
| + | =REMS programs= | ||
| + | *[https://www.yescartatecartusrems.com/ Axicabtagene ciloleucel (Yescarta)] | ||
| + | *[https://www.yescartatecartusrems.com/ Brexucabtagene autoleucel (Tecartus)] | ||
| + | *[https://carvyktirems.com/ Ciltacabtagene autoleucel (Carvykti)] | ||
| + | *[https://www.abecmarems.com/ Idecabtagene vicleucel (Abecma)] | ||
| + | *[https://www.breyanzirems.com/ Lisocabtagene maraleucel (Breyanzi)] | ||
| + | *[https://www.kymriah-rems.com/ Tisagenlecleucel (Kymriah)] | ||
[[Category:General reference pages]] | [[Category:General reference pages]] | ||
[[Category:Immunotherapy regimens]] | [[Category:Immunotherapy regimens]] | ||
[[Category:Supportive oncology]] | [[Category:Supportive oncology]] | ||
Revision as of 19:45, 16 January 2023
| Page co-editor | Page co-editor | ||
|---|---|---|---|
 |
Leyre Zubiri, MD, PhD Massachusetts General Hospital Boston, MA |
 |
Matthew Hadfield, DO Lifespan/Brown University Providence, RI |
Guidelines
ASTCT
- 2019: Lee et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells